Systemic lupus erythematosus and pregnancy

Research output: Contribution to journalArticle

Abstract

Although most women with systemic lupus erythematosus can achieve a successful pregnancy, fetal (fetal loss, preterm birth) and maternal (lupus flares, worsening renal function) morbidity remain major problems. Predictors of fetal loss and preterm birth have been identified and are reviewed. Modern management of lupus pregnancy includes identification of high-risk pregnancies with appropriate monitoring and treatment (when indicated) for anti-Ro and antiphospholipid antibodies, frequent assessment of and control of maternal lupus activity, adjustment of medications to avoid those associated with fetal teratogenicity, and the appropriate use of fetal assessment tests to guide intervention for the fetus at risk of intra-uterine death.

Original languageEnglish (US)
Pages (from-to)87-118
Number of pages32
JournalRheumatic Disease Clinics of North America
Volume20
Issue number1
StatePublished - 1994

Fingerprint

Premature Birth
Systemic Lupus Erythematosus
Mothers
High-Risk Pregnancy
Pregnancy
Antiphospholipid Antibodies
Anti-Idiotypic Antibodies
Fetus
Morbidity
Kidney
Therapeutics
SS-A antibodies

ASJC Scopus subject areas

  • Rheumatology

Cite this

Systemic lupus erythematosus and pregnancy. / Petri, Michelle.

In: Rheumatic Disease Clinics of North America, Vol. 20, No. 1, 1994, p. 87-118.

Research output: Contribution to journalArticle

@article{b86b4e62d9ed464badc104c9c3e93ad0,
title = "Systemic lupus erythematosus and pregnancy",
abstract = "Although most women with systemic lupus erythematosus can achieve a successful pregnancy, fetal (fetal loss, preterm birth) and maternal (lupus flares, worsening renal function) morbidity remain major problems. Predictors of fetal loss and preterm birth have been identified and are reviewed. Modern management of lupus pregnancy includes identification of high-risk pregnancies with appropriate monitoring and treatment (when indicated) for anti-Ro and antiphospholipid antibodies, frequent assessment of and control of maternal lupus activity, adjustment of medications to avoid those associated with fetal teratogenicity, and the appropriate use of fetal assessment tests to guide intervention for the fetus at risk of intra-uterine death.",
author = "Michelle Petri",
year = "1994",
language = "English (US)",
volume = "20",
pages = "87--118",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Systemic lupus erythematosus and pregnancy

AU - Petri, Michelle

PY - 1994

Y1 - 1994

N2 - Although most women with systemic lupus erythematosus can achieve a successful pregnancy, fetal (fetal loss, preterm birth) and maternal (lupus flares, worsening renal function) morbidity remain major problems. Predictors of fetal loss and preterm birth have been identified and are reviewed. Modern management of lupus pregnancy includes identification of high-risk pregnancies with appropriate monitoring and treatment (when indicated) for anti-Ro and antiphospholipid antibodies, frequent assessment of and control of maternal lupus activity, adjustment of medications to avoid those associated with fetal teratogenicity, and the appropriate use of fetal assessment tests to guide intervention for the fetus at risk of intra-uterine death.

AB - Although most women with systemic lupus erythematosus can achieve a successful pregnancy, fetal (fetal loss, preterm birth) and maternal (lupus flares, worsening renal function) morbidity remain major problems. Predictors of fetal loss and preterm birth have been identified and are reviewed. Modern management of lupus pregnancy includes identification of high-risk pregnancies with appropriate monitoring and treatment (when indicated) for anti-Ro and antiphospholipid antibodies, frequent assessment of and control of maternal lupus activity, adjustment of medications to avoid those associated with fetal teratogenicity, and the appropriate use of fetal assessment tests to guide intervention for the fetus at risk of intra-uterine death.

UR - http://www.scopus.com/inward/record.url?scp=0028012384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028012384&partnerID=8YFLogxK

M3 - Article

C2 - 8153405

AN - SCOPUS:0028012384

VL - 20

SP - 87

EP - 118

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 1

ER -